Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:34 AM
Ignite Modification Date:
2025-12-25 @ 2:34 AM
NCT ID:
NCT06180434
Eligibility Criteria:
Inclusion Criteria:
* Histopathologically confirmed WHO grade 2 or grade WHO 3 IDHmt glioma
* Treatment with radiotherapy delivered between 1 of January 2018 and completed before or on the 30th of June 2022
* Treatment with chemotherapy delivered after radiotherapy (PCV or Temozolomide)
* Age ≥ 18 years
Exclusion Criteria:
* Prior cranial radiotherapy
* Contra-indication for MRI imaging
* Chemotherapy delivered before radiotherapy
* Dose and fractionation other that standard dose (50.4 Gy in 28 fractions for Grade 2 and 59.5 Gy in 33 fractions for Grade 3)
* Combination photon and proton therapy
* Patient has previously opted-out of the use of their data for research
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT06180434
Study Brief:
Protocol Section:
NCT06180434